Supplementary Figures

Figure S1. Funnel plot of the studies that assessed the risk of respiratory tract infections with IL-12/23 and IL-23 antagonists. Begg’s test P = 0.67; Egger’s tests P = 0.065. Figure S2. Meta-analysis of Mantel Haenszel risk difference of respiratory tract infections (RTIs) with IL-12/23 and IL-23 antagonists to assess the differential risk of RTIs by underlying autoimmune diseases. Figure S3. (A) Meta-analysis of Mantel Haenszel risk difference of upper respiratory tract infections with IL-12/23 and IL-23 antagonists. (B) Funnel plot of the studies that assessed the risk of upper respiratory tract infections with IL-12/23 and IL-23 antagonists. Begg’s test P = 0.81; Egger’s tests P = 0.46. Figure S4. (A) Meta-analysis of Mantel Haenszel risk difference of viral upper respiratory tract infections with IL-12/23 and IL-23 antagonists. (B) Funnel plot of the studies that assessed the risk of viral upper respiratory tract infections with IL-12/23 and IL-23 antagonists. Begg’s test P < 0.001; Egger’s tests P = 0.019. Figure S5. (A) Meta-analysis of Mantel Haenszel risk difference of lower respiratory tract infections with IL-12/23 and IL-23 antagonists. (B) Funnel plot of the studies that assessed the risk of lower respiratory tract infections with IL-12/23 and IL-23 antagonists. Begg’s test P < 0.001; Egger’s tests P = 0.55. Figure S6. Funnel plot of the studies that assessed the risk of infectious pneumonia with IL-12/23 and IL-23 antagonists. Begg’s test P < 0.001; Egger’s tests P = 0.93. Figure S7. Funnel plot of the studies that assessed the risk of non-infectious ILD with IL-12/23 and IL-23 antagonists. Begg’s test P < 0.001; Egger’s tests P = 0.69.

图S1. 评估白介素-12/23与白介素-23拮抗剂相关呼吸道感染风险的研究漏斗图。Begg检验P=0.67；Egger检验P=0.065。
图S2. 采用曼特尔-亨塞尔风险差法开展的Meta分析，旨在基于基础自身免疫性疾病评估白介素-12/23与白介素-23拮抗剂相关呼吸道感染的差异风险。
图S3. (A) 评估白介素-12/23与白介素-23拮抗剂相关上呼吸道感染风险的曼特尔-亨塞尔风险差Meta分析。(B) 评估白介素-12/23与白介素-23拮抗剂相关上呼吸道感染风险的研究漏斗图。Begg检验P=0.81；Egger检验P=0.46。
图S4. (A) 评估白介素-12/23与白介素-23拮抗剂相关病毒性上呼吸道感染风险的曼特尔-亨塞尔风险差Meta分析。(B) 评估白介素-12/23与白介素-23拮抗剂相关病毒性上呼吸道感染风险的研究漏斗图。Begg检验P<0.001；Egger检验P=0.019。
图S5. (A) 评估白介素-12/23与白介素-23拮抗剂相关下呼吸道感染风险的曼特尔-亨塞尔风险差Meta分析。(B) 评估白介素-12/23与白介素-23拮抗剂相关下呼吸道感染风险的研究漏斗图。Begg检验P<0.001；Egger检验P=0.55。
图S6. 评估白介素-12/23与白介素-23拮抗剂相关感染性肺炎风险的研究漏斗图。Begg检验P<0.001；Egger检验P=0.93。
图S7. 评估白介素-12/23与白介素-23拮抗剂相关非感染性间质性肺疾病(Interstitial Lung Disease, ILD)风险的研究漏斗图。Begg检验P<0.001；Egger检验P=0.69。